Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otenabant in prevention of weight regain in obesity
NCT00483171Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Otenabant Arm with Placebo Arm (2 arms). Primary endpoint: Percent weight regained during the 12 month treatment period at 14 months. Started Jan 2008; status: terminated.
02
Drugs
otenabant
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00483171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483171.